Astria Therapeutics (NASDAQ:ATXS) Receives Buy Rating from HC Wainwright

Astria Therapeutics (NASDAQ:ATXS)‘s stock had its “buy” rating restated by HC Wainwright in a note issued to investors on Monday,Benzinga reports. They currently have a $16.00 price target on the biotechnology company’s stock. HC Wainwright’s price target would suggest a potential upside of 118.58% from the company’s current price.

Separately, Oppenheimer upped their target price on shares of Astria Therapeutics from $26.00 to $28.00 and gave the stock an “outperform” rating in a research note on Thursday, November 14th. Five research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the stock has an average rating of “Buy” and a consensus target price of $25.60.

Astria Therapeutics Price Performance

Shares of NASDAQ:ATXS traded down $0.13 during mid-day trading on Monday, hitting $7.32. The company had a trading volume of 34,277 shares, compared to its average volume of 201,305. The firm has a fifty day moving average price of $9.85 and a 200 day moving average price of $10.70. Astria Therapeutics has a one year low of $6.94 and a one year high of $16.90. The company has a market capitalization of $413.10 million, a PE ratio of -3.50 and a beta of 0.70.

Institutional Investors Weigh In On Astria Therapeutics

Hedge funds have recently made changes to their positions in the business. FMR LLC grew its position in shares of Astria Therapeutics by 29.2% during the 3rd quarter. FMR LLC now owns 7,822,275 shares of the biotechnology company’s stock valued at $86,123,000 after acquiring an additional 1,767,714 shares during the period. Vestal Point Capital LP lifted its stake in Astria Therapeutics by 23.1% in the third quarter. Vestal Point Capital LP now owns 4,000,000 shares of the biotechnology company’s stock valued at $44,040,000 after purchasing an additional 750,000 shares during the last quarter. Nantahala Capital Management LLC bought a new position in Astria Therapeutics during the second quarter valued at $6,142,000. Redmile Group LLC purchased a new stake in Astria Therapeutics in the third quarter worth $3,423,000. Finally, Cubist Systematic Strategies LLC purchased a new position in shares of Astria Therapeutics during the 2nd quarter valued at $2,561,000. 98.98% of the stock is currently owned by institutional investors.

About Astria Therapeutics

Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema.